Paolo Tarantino Raises Poll on Chemotherapy Attrition in Metastatic Breast Cancer
Paolo Tarantino, 2025 Yvonne ‘Top Voice’ Award Winner, Research Fellow at Dana-Farber Cancer Institute, posted on X:
“I’ve noticed a lot of discordance between real world studies looking at treatment attrition in mBC.
Poll for medical oncologists:
How many of the patients with mBC you care for do NOT manage to receive a new line of chemo after discontinuing the first line of chemo?
5.1 percent of people voted that 40 to 60 percent of their patients with metastatic breast cancer do not go on to receive another line of chemotherapy after stopping the first line. 16.8 percent said that 20 to 40 percent of their patients don’t receive further chemotherapy.
39.1 percent responded that only 0 to 20 percent of their patients miss out on additional chemo. Another 39.1 percent selected the option indicating they just wanted to see the results or are not medical oncologists.”
More posts featuring Paolo Tarantino.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023